Jung‐Min Lee

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Erika J. Lampert, Alexandra S. Zimmer, Michelle R. Padget et al. · Clinical Cancer Research · 2020 · 221 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells

In-Young Jung, Yoon-Young Kim, Ho-Sung Yu et al. · Cancer Research · 2018 · 220 citations · Full text

Life Sciences, Immunology, Oncology +17

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

Jung‐Min Lee, Jayakumar R. Nair, Alexandra S. Zimmer et al. · The Lancet Oncology · 2018 · 212 citations · Full text

Medicine, Gynecology, Oncology +13

The long-run impact of a traumatic experience on risk aversion

Young Il Kim, Jung‐Min Lee · Journal of Economic Behavior & Organization · 2014 · 201 citations

Social Sciences, Behavioral Sciences, Psychology +15

Establishment of Blood Glucose Monitoring System Using the Internet

Hyuk‐Sang Kwon, Jae‐Hyoung Cho, Hee‐Soo Kim et al. · Diabetes Care · 2004 · 200 citations

Medicine, Health Informatics, Internal Medicine +17